WO2022101805 - HYPERIMMUNE GLOBULINS FOR TREATMENT OF CHIKUNGUNYA VIRUS INFECTIONS
National phase entry is expected:
Publication Number
WO/2022/101805
Publication Date
19.05.2022
International Application No.
PCT/IB2021/060416
International Filing Date
10.11.2021
Title **
[English]
HYPERIMMUNE GLOBULINS FOR TREATMENT OF CHIKUNGUNYA VIRUS INFECTIONS
[French]
GLOBULINES HYPERIMMUNES POUR LE TRAITEMENT D'INFECTIONS PAR LE VIRUS CHIKUNGUNYA
Applicants **
EMERGENT BIOSOLUTIONS CANADA INC.
155 Innovation Drive
Winnipeg, Manitoba R3T 5Y3, CA
Inventors
NYKIFORUK, Cory
c/o Emergent Biosolutions Canada Inc.
155 Innovation Drive
Winnipeg, Manitoba R3T 5Y3, CA
HAN, Xiaobing
c/o Emergent Biosolutions Canada Inc.
155 Innovation Drive
Winnipeg, Manitoba R3T 5Y3, CA
KODIHALLI, Shantha
c/o Emergent Biosolutions Canada Inc.
155 Innovation Drive
Winnipeg, Manitoba R3T 5Y3, CA
BARKER, Douglas
c/o Emergent Biosolutions Canada Inc.
155 Innovation Drive
Winnipeg, Manitoba R3T 5Y3, CA
Priority Data
63/113,753
13.11.2020
US
63/227,492
30.07.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
CIPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 2127 | |
| EPO | Filing, Examination | 17330 | |
| Japan | Filing | 591 | |
| South Korea | Filing | 607 | |
| USA | Filing, Examination | 10310 |
Total: 30965 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present disclosure is directed to methods of using mixtures of anti-Chikungunya virus (CHIKV) antibodies and/or antigen-binding fragments thereof to treat CHIKV infections in human patients.[French]
La présente invention concerne des procédés d'utilisation de mélanges d'anticorps anti-virus du Chikungunya (CHIKV) et/ou de fragments de liaison à l'antigène de ceux-ci pour traiter des infections par le CHIKV chez des patients humains.